Dr Antonio Frasca provides a wealth of biomedical science and biomed tech development expertise, with 14 years of experience as an academic scientist at Columbia University, The University of Pennsylvania, The Icahn School of Medicine at Mount Sinai, and New York University.
In the course of his academic work, Antonio conceived and validated foundational hypotheses opening new vistas for the understanding of disease and the development of interventional biotechnologies in diverse fields, including developmental epigenetics, cardiovascular surgery, and critical care. Antonio is also himself an inventor of several intellectual properties. These include protective modifications against deleterious biochemical mechanisms for interventional biomaterials as well as enhanced testing paradigms for biomaterial-based medical device development and personalized medicine applications. Antonio has been an invited participant in major biomed tech accelerator programs, received top prize from the competitive BiomedX program at Columbia University for his biomaterial modification technology, and has successfully engaged major biotech venture capital firms for biotech spinout funding.
Antonio received his Bachelor’s in Biochemistry from Columbia University and his PhD in Biomedical Sciences with a focus on Epigenetics from the Icahn School of Medicine at Mount Sinai.